Media
Focus on the development of new antibody drugs for the treatment of tumors and autoimmune inflammatory diseases

Media

新闻动态
/
/
/
Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.

Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.

  • Categories:Press Release
  • Author:
  • Origin:
  • Time of issue:2019-02-19 13:51
  • Views:

(Summary description)Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.

Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.

(Summary description)Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.

  • Categories:Press Release
  • Author:
  • Origin:
  • Time of issue:2019-02-19 13:51
  • Views:
Information

Feb.19th, 2020 The IND application of “Recombinant anti-human IL-17A / F humanized monoclonal antibody injection” is approved by NMPA.

Scan the QR code to read on your phone

这是描述信息

Add

Zhong Guancun Biopharmaceutical Park, NO.5 Kaituo Road,

Haidian District, Beijing City, China, 10084

A1 Northern Building, 218 Xinghu St. Suzhou Industrial Park, Jiangsu Province, China, 215123

COPYRIGHT @2020 Suzhou xinkanghe Biomedical Technology Co., Ltd   京ICP备12345678   Power by 300.cn Beijing

这是描述信息

Follow us